Latest Breaking News On - Shabir hasham - Page 1 : comparemela.com

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating

United statesUnited kingdomSwitzerland generalShabir hashamDario eklundAndrew smithEva kaliasChiesi farmaceuticiAmerica to catalyst pharmaceuticals incLife science allianceNational institute for healthSanthera pharmaceuticals holdingCatalyst pharmaceuticals incExchange regulation ltdRegulatory agencySanthera pharmaceuticals holding ltd

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSwitzerland generalUnited statesDennis riedlEva kaliasDario eklundShabir hashamChiesi farmaceuticiAndrew smithSanthera pharmaceuticalsChina national medical products administrationCatalyst pharmaceuticalsHead investor relations communicationsExchange regulationEuropean medicines agencyEuropean union summary of product characteristics

MHRA approves Santhera s Duchenne muscular dystrophy drug Agamree

MHRA approves Santhera s Duchenne muscular dystrophy drug Agamree
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesShabir hashamEuropean commissionNational institute for healthRegulatory agencyDrug administrationAmerica to catalyst pharmaceuticalsSanthera pharmaceutical agamreeNational instituteCare excellenceNorth americaCatalyst pharmaceuticals

MHRA approves safer medicine alternative for rare disease

MHRA approves safer medicine alternative for rare disease
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United kingdomShabir hashamEuropean commissionSanthera pharmaceuticalsRegulatory agencyUnited kingdom medicinesChief medical officerChief executiveDuchenne united kingdomAlex johnsonJoining jack

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalUnited kingdomEva kaliasShabir hashamLife science allianceEuropean unionRegulatory agencyHead investor relations communicationsSanthera pharmaceuticals holdingAmerica to catalyst pharmaceuticalsDuchenne research fundSanthera pharmaceuticalsEuropean medicines agencyEnergyx ray absorptiometryDrug administration